TEVA · Teva Pharmaceutical Industries Ltd · Documents
Market Cap
$46.21B
Shares
1.17B
Volume · Oct 21
4.6M
Avg daily vol (3M)
5.68M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| Investor Event Transcript | Teva’s Welltruza won US FDA approval as a once-monthly subcutaneous olanzapine long-acting injectable with no loading dose or oral supplementation. Teva expects meaningful revenue in the second half of next year and set the WAC price at $3,950. | 2026-10-09 | 2026-12-31 | |
| Investor Event Transcript | — | 2026-09-23 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-22 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-22 | 2026-09-30 | |
| 8-K | — | 2026-09-16 | — | |
| Investor Event Transcript | — | 2026-09-14 | 2026-09-30 | |
| 8-K | — | 2026-09-14 | — | |
| 8-K | — | 2026-09-11 | 2026-09-09 | |
| 8-K | — | 2026-09-03 | — | |
| 8-K | — | 2026-09-03 | 2026-08-31 | |
| 8-K | — | 2026-07-29 | — | |
| 10-Q | — | 2026-07-29 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-08 | 2026-06-30 | |
| 8-K | — | 2026-05-28 | — | |
| 10-Q | — | 2026-04-29 | 2026-03-31 | |
| 8-K | — | 2026-04-29 | — | |
| DEFA14A | — | 2026-03-31 | — | |
| DEF 14A | — | 2026-03-31 | 2026-05-28 | |
| ARS | — | 2026-03-31 | 2025-12-31 | |
| Investor Event Transcript | — | 2026-03-10 | 2026-03-31 | |
| 10-K | — | 2026-02-03 | 2025-12-31 | |
| 8-K | — | 2026-01-28 | — | |
| 8-K | — | 2026-01-12 | 2026-01-11 | |
| 8-K | — | 2025-12-11 | 2025-12-10 | |
| 10-Q | — | 2025-11-05 | 2025-09-30 | |
| 8-K | — | 2025-11-05 | — | |
| 8-K | — | 2025-07-30 | — | |
| 10-Q | — | 2025-07-30 | 2025-06-30 | |
| 8-K | — | 2025-06-05 | — | |
| 8-K | — | 2025-05-28 | — | |
| 8-K | — | 2025-05-22 | 2025-05-20 | |
| 8-K | — | 2025-05-07 | — | |
| 10-Q | — | 2025-05-07 | 2025-03-31 | |
| DEF 14A | — | 2025-04-09 | 2025-06-05 | |
| DEFA14A | — | 2025-04-09 | — | |
| ARS | — | 2025-04-09 | 2024-12-31 | |
| Investor Event Transcript | — | 2025-02-24 | 2025-03-31 | |
| S-3ASR | — | 2025-02-07 | — | |
| 10-K | — | 2025-02-05 | 2024-12-31 | |
| 8-K | — | 2025-01-29 | — | |
| 8-K | — | 2024-11-12 | 2024-11-05 | |
| 8-K | — | 2024-11-06 | — | |
| 10-Q | — | 2024-11-06 | 2024-09-30 | |
| 10-Q | — | 2024-07-31 | 2024-06-30 | |
| 8-K | — | 2024-07-31 | — | |
| 8-K | — | 2024-06-25 | 2024-06-23 | |
| 8-K | — | 2024-06-06 | — | |
| 8-K | — | 2024-05-15 | — | |
| 10-Q | — | 2024-05-08 | 2024-03-31 | |
| 8-K | — | 2024-05-08 | — |
Showing 1–50 of 127 filings
Key facts
CIK
818686
CUSIP
M8769Q102
13F (30d)
98 filings
86 filers
Visit website
Investor relations